{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:58:31Z","timestamp":1791687511628,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.gore.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:31:37Z","timestamp":1565724697000},"page":"102-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["BRCA mutation in high grade epithelial ovarian cancers"],"prefix":"10.1016","volume":"29","author":[{"given":"Tarinee","family":"Manchana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Phoolcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patou","family":"Tantbirojn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2019.07.007_bb0005","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","article-title":"Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review","volume":"61","author":"Arts-de Jong","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2019.07.007_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.gore.2019.07.007_bb0020","doi-asserted-by":"crossref","first-page":"85529","DOI":"10.18632\/oncotarget.13456","article-title":"Prevalence and clinical significance of BRCA1\/2 germline and somatic mutations in Taiwanese patients with ovarian cancer","volume":"7","author":"Chao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gore.2019.07.007_bb0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/jog.13287","article-title":"High-risk epithelial ovarian cancer patients for hereditary ovarian cancer","volume":"43","author":"Chirasophon","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.gore.2019.07.007_bb0030","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/IGC.0000000000000529","article-title":"Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations","volume":"25","author":"Choi","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.gore.2019.07.007_bb0035","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e43","article-title":"Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube","volume":"29","author":"Choi","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP inhibitors in ovarian cancer: evidence, experience and clinical potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0045","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2015.11.001","article-title":"Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients","volume":"141","author":"Hasmad","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2019.07.007_bb0050","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e61","article-title":"Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates","volume":"28","author":"Helpman","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0055","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2019.07.007_bb0065","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0070","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00432-009-0607-3","article-title":"BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients","volume":"135","author":"Lim","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.gore.2019.07.007_bb0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.18632\/oncotarget.6834","article-title":"BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","volume":"7","author":"Mafficini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gore.2019.07.007_bb0080","first-page":"1","article-title":"Survival outcomes for different subtypes of epithelial ovarian cancer","volume":"1","author":"Manchana","year":"2018","journal-title":"Clin. Res. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2019.07.007_bb0085","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2019.07.007_bb0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.gore.2019.07.007_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ijms17122113","article-title":"Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment","volume":"17","author":"Rojas","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gore.2019.07.007_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.29707","article-title":"BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2019.07.007_bb0105","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","article-title":"The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients","volume":"27","author":"Wu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2019.07.007_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:52Z","timestamp":1762480552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578919300694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":22,"alternative-id":["S2352578919300694"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2019.07.007","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA mutation in high grade epithelial ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}